Evaluation of the validity and screening performance of a revised single‐item fear of cancer recurrence screening measure (FCR‐1r)
Open Access
- 30 April 2023
- journal article
- research article
- Published by Wiley in Psycho-Oncology
- Vol. 32 (6) , 961-971
Abstract
Objective: Fear of cancer recurrence (FCR) is highly prevalent among cancer survivors, but irregularly identified in practice. Single‐item FCR measures suitable for integration into broader psychosocial screening are needed. This study evaluated the validity of a revised version of the original FCR‐1 (FCR‐1r) and screening performance alongside the Edmonton Symptom Assessment System – Revised (ESAS‐r) anxiety item.Methods: The FCR‐1r was adapted from the FCR‐1 and modelled on the ESAS‐r. Associations between FCR‐1r and FCR Inventory‐Short Form (FCRI‐SF) scores determined concurrent validity. Relationships of FCR‐1r scores with variables related (e.g., anxiety, intrusive thoughts) and unrelated (e.g., employment/marital status) to FCR determined convergent and divergent validity respectively. A Receiver‐Operating Characteristic analysis examined screening performance and cut‐offs for the FCR‐1r and ESAS‐r anxiety item.Results: 107 participants were recruited in two studies (Study 1, July‐October 2021, n = 54; Study 2: November 2021‐May 2022, n = 53). The FCR‐1r demonstrated concurrent validity against the FCRI‐SF (r = 0.83, p < 0.0001) and convergent validity versus the Generalised Anxiety Disorder‐7 (r = 0.63, p < 0.0001) and Impact of Event Scale‐Revised Intrusion subscale (r = 0.55, p < 0.0001). It did not correlate with unrelated variables (e.g., employment/marital status), indicating divergent validity. An FCR‐1r cut‐off ≥5/10 had 95% sensitivity and 77% specificity for detecting clinical FCR (area under the curve (AUC) = 0.91, 95% CI 0.85–0.97, p < 0.0001); ESAS‐r anxiety cut‐off ≥4 had 91% sensitivity and 82% specificity (AUC = 0.87, 95% CI 0.77–0.98, p < 0.0001).Conclusions: The FCR‐1r is a valid and accurate tool for FCR screening. Further evaluation of the screening performance of the FCR‐1r versus the ESAS‐r anxiety item in routine care is needed.Keywords
Funding Information
- Cancer Institute NSW
This publication has 28 references indexed in Scilit:
- Exploring the screening capacity of the Fear of Cancer Recurrence Inventory‐Short Form for clinical levels of fear of cancer recurrencePsycho-Oncology, 2017
- Current approaches to managing fear of cancer recurrence; a descriptive survey of psychosocial and clinical health professionalsPsycho-Oncology, 2013
- Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross‐sectional studyPsycho-Oncology, 2013
- Factors reported to influence fear of recurrence in cancer patients: a systematic reviewPsycho-Oncology, 2012
- Fear of recurrence and disease progression in long‐term (≥5 years) cancer survivors—a systematic review of quantitative studiesPsycho-Oncology, 2012
- Receiver Operating Characteristic Curve in Diagnostic Test AssessmentJournal of Thoracic Oncology, 2010
- The Impact of Event Scale-Revised: Psychometric properties in a sample of motor vehicle accident survivorsJournal of Anxiety Disorders, 2008
- Quality criteria were proposed for measurement properties of health status questionnairesJournal of Clinical Epidemiology, 2007
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- The Edmonton Symptom Assessment System (ESAS): A Simple Method for the Assessment of Palliative Care PatientsJournal of Palliative Care, 1991